March 24, 2025 07:41 AM EDT
Deals
R&D

No­vo Nordisk pays $200M up­front for Chi­na-based biotech’s triple-G obe­si­ty shot

Elizabeth Cairns

Senior biopharma journalist

No­vo Nordisk is not im­mune to the trend of seek­ing obe­si­ty as­sets from Chi­na-based biotechs, and the Dan­ish drug­mak­er will pay …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Lyn­dra Ther­a­peu­tics to wind down amid fund­ing hur­dles for long-act­ing drug tech­nol­o­gy

Ei­sai cuts Leqem­bi 2027 sales fore­cast by half but ex­pects 'con­tin­ued growth'

Sen­ate com­mit­tee backs Dr. Oz's nom­i­na­tion to lead CMS

WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US

DOGE pulls three FDA lease clo­sures from 'Wall of Re­ceipts,' in­clud­ing St. Louis qual­i­ty lab

Il­lu­mi­na adds ac­tivist in­vestor to board, taps for­mer FDA head as chair

A service from the Financial Times